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CONCLUSION: The CareCard Diabetes was found to be
an up-to-date standard for implementing a quality of care
initiative in Switzerland. The internet offers possibilities
to extend the value of this originally paper-based tool for
improving quality of diabetes care.
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OBJECTIVES: Type-2 diabetes increases the risk of 
cardiovascular and cerebrovascular complications. In
general population, overweight/obesity are associated
with high risk of related diseases. In a type-2 diabetes
patient’s population, we examine the relationship
between BMI status and incidence of cardiovascular and
cerebrovascular complications. METHODS: We used a
cohort of type-2 diabetes patients over a 15-year period.
Study patients were stratiﬁed in 4 BMI groups: 20–
24.9kg/m2 (normal weight), 25–29.9kg/m2 (overweight),
30–34.9kg/m2 (obese) and over 35kg/m2 (very obese).
Incidence of diseases was analyzed retrospectively 
(p < 0.05) in each BMI group relative to the “normal
weight” group. RESULTS: Five thousand four hundred
and thirty ﬁve type-2 diabetes patients were examined.
Average age was 63.61 years and 44 % of the population
was women. Number of patients per group were 1,060
normal weight, 2,072 overweight, 1,454 obese and 849
very obese. Average follow-up (734 days) and average
duration of diabetes history (15 years) were comparable
in each BMI group relative to normal weight group. Inci-
dence of myocardial infarction are 1.13%, 4.05% 
(p < 0.05, Chi2), 2.48% (p < 0,05, Chi2) and 1.53% 
(p > 0.05, Chi2); incidence of coronarography are 0.57%,
1.40% (p < 0.05, Chi2), 1.65% (p < 0.05, Chi2) and
1.77% (p < 0.05, Chi2), respectively in normal weight,
overweight, obese and very obese. PTCA and CABG are
more frequent in obese group compare to normal weight.
HbA1c is normalized (below 7%) in higher proportion of
normal weight patients (21.89%) compare to obese
(18.50%, p < 0.05, Chi2). Incidence of cerebrovascular
events such as stroke or TIA are not statistically different
according to BMI group. CONCLUSION: In this analy-
sis, variables like follow-up and duration of diabetes
history were homogeneously distributed among BMI
groups. In this cohort of type-2 diabetes patients, we
observed that cardiovascular events are more frequent in
overweight/ obese compared to normal weight. Further
research will need to conﬁrm that a relevant weight reduc-
tion would have a clinical beneﬁt in this high-risk patients
population.
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OBJECTIVES: Patient reported Treatment Satisfaction
instruments can be used to assess degree of acceptability
and effectiveness of a treatment. For diabetes, this assess-
ment can be helpful for guiding treatment decisions about
the most optimal insulin therapy regimens for a given
patient. Unfortunately, there are no instruments identi-
ﬁed in the literature that assess the full spectrum of 
satisfaction issues with insulin therapies. Therefore, we 
undertook the development and validation of the com-
prehensive Insulin Treatment Satisfaction Questionnaire
(ITSQ). METHOD: An original item pool was developed
using data collected from ﬁve focus groups with insulin
users, current literature and consultation with behavioral
diabetes researchers. The initial questionnaire was tested
in 170 diabetes patients from 3 large clinical centers in
different regions of the US who were currently using a
variety of insulin regimens. A conﬁrmatory psychometric
study in 402 insulin users was subsequently conducted.
RESULTS: Item and scale analysis with IRT and factor
analysis resulted in the identiﬁcation of six subscales:
Ease/Convenience, Interference, Lifestyle, Hypoglycemia,
Glycemic control, and Insulin Delivery System. Cronbach
alpha reliability ranged from .79 to .92, and 2-week test-
retest reliability (n = 35) ranged from 0.65 to 0.89. Con-
vergent validity of the ITSQ was established in relation
to several questionnaires, including the PAID, insulin self-
efﬁcacy and diabetes symptoms questionnaires. The ITSQ
subscales discriminated signiﬁcantly for A1c level, Type 1
vs. Type 2 diabetes, and global satisfaction. The conﬁr-
matory validation study conﬁrmed the original six-factor
structure and the discriminative validity. The ﬁnal short-
ened ITSQ contains 25 items, which may be reported as
a total score or as 6 subscale scores. CONCLUSION: The
ITSQ is a comprehensive and psychometrically valid
instrument covering six distinct dimensions of treatment
satisfaction with insulin. It is applicable to type-1 and 2
diabetes patients and a wide range of insulin regimens.
